Maddox, Judy

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine

Bone health and osteoporosis researchBone health and treatments

Cited by 1,805

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine

Bone health and osteoporosis researchBone health and treatments

Cited by 1,544

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine

Bone health and osteoporosis researchBone health and treatments

Cited by 1,258

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Langdahl, B. L., Libanati, C., Crittenden, D. B., Bolognese, M. A., Brown, J. P., Daizadeh, N. S., Dokoupilova, E., Engelke, K., Finkelstein, J. S., Genant, H. K., et al. (2017) · The Lancet

Bone health and osteoporosis researchBone health and treatments

Cited by 497